Exelixis, Inc. (EXEL)
69.00
-0.84
(-1.20%)
USD |
NASDAQ |
Nov 13, 10:06
Exelixis Enterprise Value : 16.36B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 16.36B |
| November 11, 2026 | 16.57B |
| November 10, 2026 | 16.54B |
| November 09, 2026 | 16.82B |
| November 06, 2026 | 16.29B |
| November 05, 2026 | 16.08B |
| November 04, 2026 | 17.07B |
| November 03, 2026 | 16.96B |
| November 02, 2026 | 16.43B |
| October 30, 2026 | 16.25B |
| October 29, 2026 | 15.47B |
| October 28, 2026 | 15.49B |
| October 27, 2026 | 15.26B |
| October 26, 2026 | 15.20B |
| October 23, 2026 | 15.06B |
| October 22, 2026 | 15.25B |
| October 21, 2026 | 15.07B |
| October 20, 2026 | 15.02B |
| October 19, 2026 | 14.61B |
| October 16, 2026 | 14.50B |
| October 15, 2026 | 14.64B |
| October 14, 2026 | 14.19B |
| October 13, 2026 | 13.83B |
| October 12, 2026 | 13.91B |
| October 09, 2026 | 13.92B |
| Date | Value |
|---|---|
| October 08, 2026 | 13.71B |
| October 07, 2026 | 13.57B |
| October 06, 2026 | 13.54B |
| October 05, 2026 | 13.67B |
| October 02, 2026 | 13.56B |
| October 01, 2026 | 13.45B |
| September 30, 2026 | 13.56B |
| September 29, 2026 | 13.92B |
| September 28, 2026 | 13.85B |
| September 25, 2026 | 13.80B |
| September 24, 2026 | 13.75B |
| September 23, 2026 | 13.45B |
| September 22, 2026 | 13.80B |
| September 21, 2026 | 13.57B |
| September 18, 2026 | 13.85B |
| September 17, 2026 | 13.88B |
| September 16, 2026 | 13.46B |
| September 15, 2026 | 13.49B |
| September 14, 2026 | 13.32B |
| September 11, 2026 | 13.29B |
| September 10, 2026 | 13.62B |
| September 09, 2026 | 13.84B |
| September 08, 2026 | 13.68B |
| September 04, 2026 | 14.01B |
| September 03, 2026 | 14.04B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 14.45B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Cytokinetics, Inc. | 7.958B |
| Gilead Sciences, Inc. | 226.62B |
| Ionis Pharmaceuticals, Inc. | 4.834B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 218.10M |
| Revenue (Quarterly) | 658.70M |
| Total Expenses (Quarterly) | 440.60M |
| EPS Diluted (Quarterly) | 0.8528 |
| Gross Profit Margin (Quarterly) | 96.02% |
| Profit Margin (Quarterly) | 33.11% |
| Earnings Yield | 4.84% |
| Operating Earnings Yield | 5.50% |
| Normalized Earnings Yield | 4.845 |